Latest Trials Latest NewsFAQ

Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Study in Healthy Men to Test How BI 1265162 is Taken up and Processed by the Body

Phase 1

Terminated

Conditions: Healthy Volunteers

First Posted Date: 2020-02-12

Last Posted Date: 2022-06-01

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 7

Registration Number: NCT04267276

Locations: 🇳🇱
PRA Health Sciences Onderzoekscentrum Martini, Groningen, Netherlands

SITS-IVT in Patients >80 Years Study

Completed

Conditions: Ischaemic Stroke

Interventions: Drug: Alteplase

First Posted Date: 2020-02-07

Last Posted Date: 2024-07-05

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 1655

Registration Number: NCT04260347

Locations: 🇸🇪
Karolinska University Hospital, Stockholm, Sweden

A Study in Healthy Men to Test the Influence of BI 1323495 on the Amount of the Medicines Rosuvastatin and Dabigatran in the Blood

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Rosuvastatin + BI 1323495
Drug: Rosuvastatin
Drug: Dabigatran etexilate
Drug: Dabigatran etexilate + BI 1323495

First Posted Date: 2020-02-05

Last Posted Date: 2024-02-23

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 28

Registration Number: NCT04257032

Locations: 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany

Early Intervention Efficacy in COPD

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: Tiotropium/Olodaterol
Drug: Tiotropium

First Posted Date: 2020-01-30

Last Posted Date: 2022-06-14

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 6788

Registration Number: NCT04249310

Locations: 🇯🇵
Nara Medical University, Nara, Japan

A Study to Test How Well Healthy Men and Women Tolerate Different Doses of BI 706321

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: BI 703621
Drug: Placebo
Drug: Midazolam

First Posted Date: 2020-01-27

Last Posted Date: 2021-01-12

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 39

Registration Number: NCT04241458

Locations: 🇧🇪
SGS Life Science Services - Clinical Research, Antwerpen, Belgium

A Study to Test How Well Empagliflozin Works in Chinese Patients With Type 2 Diabetes Who Already Take Insulin

Phase 3

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Placebo
Drug: Empagliflozin

First Posted Date: 2020-01-18

Last Posted Date: 2023-12-15

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 219

Registration Number: NCT04233801

Locations: 🇨🇳
Peking University People's Hospital, Beijing, China
🇨🇳
The First Affiliated Hospital of Nanchang University, Nanchang, China
🇨🇳
Centre Hospital of Putuo District, Shanghai, Shanghai, China

and more 21 locations

A Study in Healthy Men to Find the Best Formulation of BI 894416 and to Test How This is Taken up in the Body

Phase 1

Terminated

Conditions: Healthy

Interventions: Drug: BI 894416 Reference Formulation
Drug: BI 894416 Formulation A2
Drug: BI 894416 Formulation C2
Drug: BI 894416 Formulation D2
Drug: BI 894416 Formulation F2

First Posted Date: 2020-01-18

Last Posted Date: 2021-11-09

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 24

Registration Number: NCT04232839

Locations: 🇬🇧
Quotient Sciences, Nottingham, United Kingdom

A Study to Test the Combination of Tiotropium and Olodaterol Using the Respimat® Inhaler in People With Chronic Obstructive Pulmonary Disease (COPD) Who Have Different Abilities to Inhale

Phase 4

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: Tiotropium + olodaterol
Drug: Placebo

First Posted Date: 2020-01-10

Last Posted Date: 2021-11-18

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 213

Registration Number: NCT04223843

Locations: 🇺🇸
Meris Clinical Research, Brandon, Florida, United States
🇺🇸
Clinical Research Specialists LLC, Kissimmee, Florida, United States
🇩🇪
Klinische Forschung Berlin GbR, Berlin, Germany

and more 22 locations

The Study Observes Afatinib as First-line Treatment in Patients With Epidermal Growth Factor Receptor (EGFR) Mutation-positive Advanced Non-small Cell Lung Cancer

Completed

Conditions: Non-squamous, Non-Small Cell Lung Cancer

Interventions: Drug: Afatinib

First Posted Date: 2019-12-20

Last Posted Date: 2024-11-05

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 72

Registration Number: NCT04206787

Locations: 🇨🇳
West China Hospital, Chengdu, China
🇨🇳
Hainan Cancer Hospital, Haikou, China
🇨🇳
First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China

and more 7 locations

A Study in Healthy Men to Test How the Body Takes up and Tolerates Different Doses of BI 474121, and Whether it Makes a Difference if BI 474121 is Taken as a Tablet or a Drink.

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 474121 oral solution
Drug: BI 474121 tablet
Drug: Placebo tablet
Drug: Placebo solution

First Posted Date: 2019-12-11

Last Posted Date: 2024-03-26

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 66

Registration Number: NCT04194645

Locations: 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy